share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/07/24 21:04

Moomoo AI 已提取核心訊息

TransCode Therapeutics announced the pricing of a public offering of 10 million shares of common stock at $0.30 per share, expecting to raise $3 million in gross proceeds. The offering is set to close on July 24, 2024, with ThinkEquity acting as the sole placement agent.The company plans to use the net proceeds primarily for product development activities, including clinical trials of its lead therapeutic candidate TTX-MC138 and related IND enabling studies, as well as working capital and general corporate purposes. As part of the placement agent compensation, TransCode will issue warrants to purchase 500,000 shares of common stock, exercisable from January 18, 2025, at $0.375 per share.The shares are being offered through a shelf registration statement filed with the SEC. The offering includes placement agent warrants that will expire on July 22, 2029, issued under Section 4(a)(2) exemption of the Securities Act.
TransCode Therapeutics announced the pricing of a public offering of 10 million shares of common stock at $0.30 per share, expecting to raise $3 million in gross proceeds. The offering is set to close on July 24, 2024, with ThinkEquity acting as the sole placement agent.The company plans to use the net proceeds primarily for product development activities, including clinical trials of its lead therapeutic candidate TTX-MC138 and related IND enabling studies, as well as working capital and general corporate purposes. As part of the placement agent compensation, TransCode will issue warrants to purchase 500,000 shares of common stock, exercisable from January 18, 2025, at $0.375 per share.The shares are being offered through a shelf registration statement filed with the SEC. The offering includes placement agent warrants that will expire on July 22, 2029, issued under Section 4(a)(2) exemption of the Securities Act.
TransCode Therapeutics宣佈了公開發行1000萬股普通股的定價,發行價爲每股0.30美元,預計募集到300萬美元的總收入。此次發行預計於2024年7月24日結束,ThinkEquity將作爲唯一的安置代理。該公司計劃將淨收入主要用於產品開發活動,包括其主要治療候選藥物TTX-MC138的臨牀試驗和相關的IND啓用研究,以及營運資金和一般公司用途。作爲安置代理的補償,TransCode將發行Warrants,允許購買500,000股普通股,行使價格從2025年1月18日開始爲每股0.375美元。該股票通過向SEC提交的貨架註冊聲明進行發行。此次發行包括將在2029年7月22日到期的安置代理Warrants,依據證券法第4(a)(2)條豁免條款發行。
TransCode Therapeutics宣佈了公開發行1000萬股普通股的定價,發行價爲每股0.30美元,預計募集到300萬美元的總收入。此次發行預計於2024年7月24日結束,ThinkEquity將作爲唯一的安置代理。該公司計劃將淨收入主要用於產品開發活動,包括其主要治療候選藥物TTX-MC138的臨牀試驗和相關的IND啓用研究,以及營運資金和一般公司用途。作爲安置代理的補償,TransCode將發行Warrants,允許購買500,000股普通股,行使價格從2025年1月18日開始爲每股0.375美元。該股票通過向SEC提交的貨架註冊聲明進行發行。此次發行包括將在2029年7月22日到期的安置代理Warrants,依據證券法第4(a)(2)條豁免條款發行。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息